Comparison of the effects of different intravenous fat emulsions in patients with systemic inflammatory response syndrome and sepsis
Loading...
Date
Journal Title
Journal ISSN
Volume Title
Publisher
Open Access Color
Green Open Access
Yes
OpenAIRE Downloads
OpenAIRE Views
Publicly Funded
No
Abstract
Background: In this study, the authors aimed to compare the effects that a medium- and long-chain triglyceride (MCT/LCT) fat infusion and a fish oil-based (?-3) fat infusion for parenteral nutrition (PN) had on systemic inflammation, cytokine response, and hepatic steatosis in mixed intensive care unit (ICU) patients. Methods: This was a single-center, placebo-controlled, randomized clinical trial in a university hospital. Four patient groups, including systemic inflammatory response syndrome (SIRS) and sepsis patients, were assigned to receive PN employing the MCT/LCT fat infusion or the fish oil-based fat infusion over 7 days. Blood biochemistry and liver steatosis were evaluated. Results: Twenty sepsis and 20 SIRS patients were included in this study. There was no statistically significant difference in terms of biochemical values and Acute Physiology and Chronic Health Evaluation II scores between the different feeding groups. Sepsis groups who received MCT/LCT revealed higher grades of liver steatosis by ultrasound on days 7 and 10 (P <.05). Tumor necrosis factor (TNF)-? and interleukin (IL)-6 values in sepsis group 1 (S1) were higher than in sepsis group (S2) on day 7, whereas IL-1 values were higher on days 3, 7, and 10 in group S1 than in group S2. Conversely, IL-10 values on days 3 and 7 were significantly higher in group S2. Conclusion: Fish oil-based fat emulsions might have anti-inflammatory and hepatoprotective effects in hyperinflammatory disease such as sepsis. © 2011 The American Society for Parenteral and Enteral Nutrition.
Description
Keywords
cytokines, fat emulsions, intravenous, fatty liver, fish oils, parenteral nutrition, sepsis, systemic inflammatory response syndrome, fish oil, interleukin 1, interleukin 10, interleukin 6, lipid emulsion, lipofundin, long chain triacylglycerol, medium chain triacylglycerol, omega 3 fatty acid, omegaven, placebo, tumor necrosis factor alpha, adult, antiinflammatory activity, APACHE, article, clinical article, controlled study, drug effect, female, human, immune response, intensive care unit, liver protection, male, randomized controlled trial, ultrasound, Adult, Aged, Fat Emulsions, Intravenous, Fatty Acids, Omega-3, Fatty Liver, Female, Fish Oils, Humans, Interleukin-1, Interleukin-10, Interleukin-6, Male, Middle Aged, Parenteral Nutrition, Prospective Studies, Sepsis, Systemic Inflammatory Response Syndrome, Triglycerides, Tumor Necrosis Factor-alpha, Male, Parenteral Nutrition, long chain triacylglycerol, fish oil, intensive care unit, immune response, sepsis, medium chain triacylglycerol, Prospective Studies, APACHE, Omega-3, clinical article, tumor necrosis factor alpha, ultrasound, adult, Fatty Acids, drug effect, article, fat emulsions, intravenous, omegaven, Middle Aged, fish oils, Systemic Inflammatory Response Syndrome, Interleukin-10, systemic inflammatory response syndrome, female, Female, lipofundin, lipid emulsion, Adult, APACHE; Adult; Aged; Fat Emulsions, Intravenous/*therapeutic use; Fatty Acids, Omega-3/blood/therapeutic use; Fatty Liver/therapy; Female; Fish Oils/therapeutic use; Humans; Interleukin-1/blood; Interleukin-10/blood; Interleukin-6/blood; Male; Middle Aged; Parenteral Nutrition/*methods; Prospective Studies; Sepsis/physiopathology/*therapy; Systemic Inflammatory Response Syndrome/physiopathology/*therapy; Triglycerides/blood/therapeutic use; Tumor Necrosis Factor-alpha/blood, Fat Emulsions, Intravenous, 610, interleukin 6, parenteral nutrition, omega 3 fatty acid, interleukin 1, Fish Oils, male, Sepsis, Fatty Acids, Omega-3, Humans, controlled study, human, Triglycerides, fatty liver, Aged, Interleukin-6, Tumor Necrosis Factor-alpha, antiinflammatory activity, cytokines, Fatty Liver, fat emulsions, liver protection, intravenous, randomized controlled trial, placebo, interleukin 10, Interleukin-1
Fields of Science
0302 clinical medicine, 03 medical and health sciences
Citation
WoS Q
Scopus Q

OpenCitations Citation Count
40
Volume
26
Issue
6
Start Page
665
End Page
671
PlumX Metrics
Citations
CrossRef : 36
Scopus : 31
PubMed : 12
Captures
Mendeley Readers : 73
SCOPUS™ Citations
33
checked on Jun 05, 2026
Web of Science™ Citations
30
checked on Jun 05, 2026
Page Views
68
checked on Jun 05, 2026
Google Scholar™


